I believe Hakim has a chip on his shoulder with the FDA. He seemed more determined in the CC. Strong fundamentals and a diversified drug pipeline still puts in the driver's seat. Elite Pharma could afford the FDA's decision last Friday, which only made the process to approve its ELI brand of opioids much smoother in the future.